Publication: Outcome of newly diagnosed high risk medulloblastoma treated with carboplatin, vincristine, cyclophosphamide and etoposide
Issued Date
2018-10-01
Resource Type
ISSN
15322653
09675868
09675868
Other identifier(s)
2-s2.0-85049011212
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Neuroscience. Vol.56, (2018), 139-142
Suggested Citation
Nongnuch Sirachainan, Samart Pakakasama, Usanarat Anurathapan, Ake Hansasuta, Mantana Dhanachai, Chaiyos Khongkhatithum, Artit Jinawath, Pat Mahachoklertwattana, Suradej Hongeng Outcome of newly diagnosed high risk medulloblastoma treated with carboplatin, vincristine, cyclophosphamide and etoposide. Journal of Clinical Neuroscience. Vol.56, (2018), 139-142. doi:10.1016/j.jocn.2018.06.028 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46276
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Outcome of newly diagnosed high risk medulloblastoma treated with carboplatin, vincristine, cyclophosphamide and etoposide
Other Contributor(s)
Abstract
© 2018 Medulloblastoma is the most common malignant brain tumor among children. Although molecular study has been included in the new classification, in developing countries with limited resources the previous Chang staging system is still used. Therefore, treatment with postoperative radiation and chemotherapy remains the standard treatment. One common complication after treatment is ototoxicity, mainly due to radiation and cisplatinum. We report a revised chemotherapy protocol, replacing cisplatinum with carboplatin in newly diagnosed medulloblastoma cases. All 23 patients in this study had high risk medulloblastoma. Mean (SD) age was 9.5 ± 3.1 years. The 5-year progression free survival (PFS), 5-year overall survival (OS), and 10-year OS were 41.8 ± 12.2%, 60.0 ± 11.2%, and 48.0 ± 14.0 respectively. Most patients had grade 3–4 hematologic toxicity. Twelve patients had hearing tests, with 11 patients having grade 0 and 1 patient having grade 1 according to the Brock criteria.